Blonanserin pharmaceutical composition with improved oral absorptivity

A technology of blonanserin and composition, which is applied in the direction of drug combination, organic active ingredients, non-effective ingredients of polymer compounds, etc., can solve the problems of incapable of industrial production, etc., to improve in vitro release, improve bioavailability, The effect of mature technology

Inactive Publication Date: 2014-02-12
TIANJIN HANKANG PHARMA BIOTECH
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] In order to improve product quality and overcome the problem of incapable of industrialized production, we have carried out a lot of design and research on technical solutions, selected the optimal prescription and process, and solved the above technical defects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blonanserin pharmaceutical composition with improved oral absorptivity
  • Blonanserin pharmaceutical composition with improved oral absorptivity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1 (existing technology)

[0082] (1) Prescription

[0083] Budan color forest 4G

[0084] Jiaojevitone 10g

[0085] Micro crystal cellulose 50g

[0086] Lactose 60g

[0087] Pre -glue starch 20g

[0088] Talc powder 1g

[0089] Magnesium 1g of Magnesium

[0090] 5%polyhone waterless ethanol -free ethanol

[0091] Made into 1000 pieces

[0092] (2) Preparation method

[0093] 5) Crush the nan -colored forest, sieve, spare; mixic cellulose, lactose, polyethyl, pre -collagenized starch, magnesium magnesium, talcum powder separately sieve, set aside;

[0094] 6) According to the amount of the prescription, the original accessories are selected, and the backup is available;

[0095] 7) Take the mixed uniformly the original auxiliary materials and use 50%ethanol solution to use 20 mesh sieve mesh, dry 50 ° C, 20

[0096] The whole grain of the mesh screen;

[0097] 8) Adjust the amount of pressure pads according to the content.

Embodiment 2

[0099] (1) Prescription

[0100] Composition 1

[0101] Budan color forest 4G

[0102] α cyclic paste 25g

[0103] Composition 2

[0104] Poacoltone 20g

[0105] Micro crystal cellulose 50g

[0106] Lactose 60g

[0107] Pre -glue starch 20g

[0108] Talc powder 1g

[0109] Magnesium 1g of Magnesium

[0110] 5%polyhone water -free ethanol solution

[0111] Made into 1000 pieces

[0112] (2) Preparation method

[0113] 1) Dry the water -solution of the nan -colored forest and α -cycling, and the spray -dried particles are obtained. The spray dry particles are mixed with the water -soluble diluentGet the mixture, directly press the film;

[0114] 2) Micro crystal cellulose, lactose, cross -linked carboxymethyl cellulose sodium, pre -collagen starch, talcum powder, and magnesium magnesium, and solid -lipidate are sieved.Complete 30-40 mesh particles, dry below 50 ° C, add lubricant, mix well, directly press the tablet;

[0115] 3) Press the tablet that contains the first and second pa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A bonanserin pharmaceutical composition with improved oral absorptivity is characterized by comprising the components by weight: a first part: 4 g of bonanserin and 25 g of alpha cyclodextrin; and a second part: 20 g of cospovidone, 50 g of microcrystalline cellulose, 60 g of lactose, 20 g of pregelatinized starch, 1 g of powdered steatile, 1 g of magnesium stearate and proper amount of a povidone anhydrous-alcohol solution with a ratio of 5%.

Description

Technical field [0001] The present invention involves a bunan forest pharmaceutical composition and its preparation method.Diversify the namura forest in the alpha cylinder, which can greatly increase the in vitro release, thereby increasing biological utilization. Background technique [0002] Schizophrenia is a disease characterized by cognitive and emotional depth divisions, which is affected by the most basic human behavior, such as language, thought, perception, and self -perception.The symptoms of the disease include a wide range, and the most common is spiritual obstacles, such as hallucinations, delusional diseases and illusions. [0003] According to statistics, the global epidemic rate of schizophrenia is 0.5 % to 1.5 %, while only 5 % of all patients who are treated can finally recover completely.In addition, because schizophrenia usually causes complications, such as anxiety disorders, depression or psychiatric drug abuse, etc. According to a survey by DataMonitor, mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/496A61K47/40A61P25/18
Inventor 兰静王志凤
Owner TIANJIN HANKANG PHARMA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap